*Medical Breakthrough: CAR-T Cell Therapy Successfully Manufactured On-Site in India* _An ICMR-funded study led by CMC Vellore has demonstrated that CAR-T cell therapy can be safely and effectively manufactured within hospital settings in India — *A First-of-its-kind Achievement For The Country.*_ *Key Highlights from the VELCART Trial:* - *100% remission in acute lymphoblastic leukemia (ALL) patients* - *50% remission in large B-cell lymphoma patients* - *80% cancer-free at 15-month median follow-up* - *~90% cost reduction vs global CAR-T therapy* - *9-day in-hospital manufacturing time* - *Minimal side effects; well-tolerated* This point-of-care (PoC) model offers a scalable, cost-effective solution for delivering advanced cancer therapy in Indian hospitals. *Study Published In:* Molecular Therapy *Lead Investigator:* Dr. Vikram Mathews, Director, CMC Vellore _*Source:* Press Trust of India (PTI), May 21, 2025_ #velcart #car_therapy #cmc #oncology #icmr #indiahealthcare #medicalinnovation